Elevated Baseline Mean Corpuscular Volume Predicts the Development of Severe Hematologic Toxicity After Lu-DOTATATE Therapy.

Lu-DOTATATE is an effective second-line treatment for metastatic or nonresectable neuroendocrine tumors. This treatment can result in hematologic severe adverse reactions (SARs). Preemptive identification of patients at risk of SARs could mitigate this risk and improve treatment safety and outcomes. Demographic and oncologic history, pretreatment laboratory values, and SAR frequency were obtained for 126 sequential patients treated with Lu-DOTATATE. Univariable and multivariable logistic regression models identified factors correlating with SARs. Relative pretreatment anemia, leukopenia, thrombocytopenia, and elevated mean corpuscular volume (MCV) were significantly correlated with SARs, with an odds ratio of 16 (95% CI, 5-65) in patients with an MCV greater than 95 fL. Pretreatment bone marrow dyscrasias, including an MCV greater than 95 fL, may predict patients at risk for SARs when treated with Lu-DOTATATE. Further study is needed to determine whether the risks of SARs outweigh the benefit in these patients.